ArticleEuropean journal of medical research2025
Influence of systemic immunoinflammatory index on major adverse cardiovascular events in patients with coronary heart disease with heart failure as assessed by propensity score matching.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Associations of systemic inflammatory indices and metabolically healthy vs. unhealthy obesity in children.Italian journal of pediatrics · 2026Article
- Article
- Systemic Immune-Inflammation Index Outperforms Conventional Inflammatory Markers in Predicting Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction.Journal of inflammation research · 2026Article
- The systemic immune-inflammation index in coronary heart disease: a narrative review of thromboinflammation, phenotype-dependent utility, and clinical translation.Frontiers in cardiovascular medicine · 2026Review
- Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivesThis research aimed to evaluate the influence of the systemic immunoinflammatory index (SII) on the development of major adverse cardiovascular events (MACE) in individuals with coronary heart disease (CHD) and heart failure (HF), as determined by propensity score matching (PSM).
methodsThe 218 patients with CHD and HF were divided into the MACE group and the non-MACE group. After balancing the baseline data of the two groups by PSM (76 cases in each group after matching, total sample 152 cases), the diagnostic value of SII for MACE was analyzed using the ROC curve to determine the optimal threshold value. The independent risk factors for MACE were analyzed using multifactorial Cox regression. Kaplan-Meier curves were employed to compare the MACE-free survival rates of patients with varying SII levels.
resultsPSM effectively balanced the baseline characteristics of the two groups, with absolute values of standardized mean difference for all variables < 0.1. Platelet counts, neutrophil counts, neutrophil-to-lymphocyte ratio, SII, C-reactive protein (CRP), and NT-proBNP levels were significantly higher in the MACE group than in the non-MACE group (P < 0.05). The ROC curve showed that the area under the curve (AUC) of SII after PSM was 0.788 (95% CI 0.714-0.860, P < 0.001), with an optimal threshold of 589.31 (sensitivity 81.58%, specificity 65.79%). Multifactorial Cox analysis showed that SII ≥ 589.31 (HR 1.92, 95% CI 1.18-3.14, P = 0.009), elevated CRP (HR 1.12, 95% CI 1.03-1.23, P = 0.010), and NT-proBNP (HR 1.01, 95% CI 1.01-1.01, P < 0.001) were independent risk factors for MACE. Kaplan-Meier analysis showed that the incidence of MACE was significantly higher in the high SII (≥ 589.31) group than in the low SII group (69.30% vs 23.40%, P < 0.05).
conclusionsElevated SII increases the risk of MACE in patients with CHD with HF and is associated with poor survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.